Clinical Trials Browser

Phase 2 × Neoplasm Metastasis × trastuzumab deruxtecan × Clear all

NCT06311214 2026-03-06

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Phase 2 Recruiting

500 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06058988 2026-02-23

Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

Phase 2 Recruiting

30 enrolled

CNS

Brain Neoplasms, Glioblastoma, Neoplasm Metastasis, Meningeal Carcinomatosis

NCT07126561 2026-01-08

Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers

Phase 2 Not yet recruiting

43 enrolled

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT04639219 2025-10-16

DPT01

Phase 2 Active not recruiting

102 enrolled 18 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT07151586 2025-09-03

ALTER

Phase 2 Not yet recruiting

260 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03248492 2025-06-26

DESTINY-Breast01

Phase 2 Terminated

253 enrolled 21 charts 1 FDA

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT04420598 2025-06-24

DEBBRAH

Phase 2 Completed

41 enrolled 32 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Meningeal Carcinomatosis

NCT03505710 2025-05-30

DESTINY-Lung01

Phase 2 Terminated

181 enrolled 17 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04014075 2025-04-03

DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

Phase 2 Completed

79 enrolled 19 charts

Tumor-Agnostic

Neoplasm Metastasis